Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
2024年6月24日 - 10:27PM
The treatment landscape for Diabetic Macular Edema (DME) continues
to evolve, with innovative therapies and emerging data
significantly shaping prescribing patterns. DME is the leading
cause of vision loss in individuals with diabetes, and as its
prevalence continues to rise, ophthalmologists are increasingly
turning to advanced treatments to manage this condition
effectively.
The latest research from
Spherix’s Q2 RealTime Dynamix™: Diabetic
Macula Edema study reveals Genentech’s Vabysmo and Regeneron’s
Eylea HD have emerged as the key players in the category with Eylea
2mg, once the gold standard, taking a back seat while Vabysmo and
Eylea HD gain traction in terms of overall preference and
satisfaction. Despite facing payer constraints, these treatments
are gaining market share and preference among US ophthalmologists
(n=102).
Recent data reveals that
Regeneron’s Eylea (2mg), and compounded bevacizumab (Avastin)
continue to be share leaders for DME. In this study, Spherix also
looked at the most-recent five prescriptions (NRx) for DME.
Notably, the last-five NRx shares of Vabysmo and Eylea HD surpass
their overall brand shares, indicating the likely continued growth
for these therapies.
Study results suggest
further that, in an ideal world without payer restraints,
respondents are divided between Vabysmo and Eylea HD as their most
preferred DME treatments due to Vabysmo’s overall efficacy and
Eylea HD’s drying effect.
Due to a high rate of
brand switching in DME, the order in which ophthalmologists
prescribe either Eylea HD or Vabysmo matters for Genentech,
Regeneron, Kodiak Sciences, 4D Molecular Therapeutics, REGENXBIO,
and other current and prospective therapy manufacturers. Slightly
more ophthalmologists are likely to prescribe Vabysmo before Eylea
HD than the inverse, and about a quarter of ophthalmologists have
no preference for order stating that the patient’s needs drive
their decision.
Prescribing in this
category is starting to look like a coin flip between Vabysmo and
Eylea HD as they are rated similarly in terms of duration of
action, drying effect and other efficacy perceptions. Thus, payer
approval and access are critical for deciding what gets prescribed
to the patient. Due to payer restrictions, 32% of ophthalmologists
report that DME patients are receiving suboptimal treatment due to
inadequate insurance coverage, and 37% believe payer requirements
for first-line treatment are leading to suboptimal care. Spherix is
closely monitoring the impact of the new permanent J-code for Eylea
HD, received April 1st, to see how it impacts relative use of the
Regeneron and Genentech brands.
Spherix Global Insights
will continue to monitor these trends and provide valuable insights
to improve patient outcomes in the treatment of DME.
RealTime Dynamix™
is an independent service providing strategic guidance through
quarterly or semiannual reports, which include market trending and
a fresh infusion of event-driven and variable content with each
wave. The reports provide an unbiased view of the competitive
landscape within rapidly evolving specialty markets, fueled by
robust HCP primary research and our in-house team of
experts.
About Spherix Global
Insights Spherix is a leading independent market
intelligence and advisory firm that delivers commercial value to
the global life sciences industry, across the brand
lifecycle.
The seasoned team of
Spherix experts provides an unbiased and holistic view of the
landscape within rapidly evolving specialty markets, including
dermatology, gastroenterology, rheumatology, nephrology, neurology,
ophthalmology, and hematology. Spherix clients stay ahead of the
curve with the perspective of the extensive Spherix Physician
Community.
As a trusted advisor and
industry thought leader, Spherix’s unparalleled market insights and
advisory services empower clients to make better decisions and
unlock opportunities for growth.
To learn more about
Spherix Global Insights, visit spherixglobalinsights.com or connect
through LinkedIn. For more details on Spherix’s primary
market research reports and interactive dashboard offerings, visit
or register
here: https://clientportal.spherixglobalinsights.com
NOTICE: All
company, brand or product names in this press release are
trademarks of their respective holders. The findings and opinions
expressed within are based on Spherix Global Insight's analysis and
do not imply a relationship with or endorsement.
Blaine Cloud, Ophthalmology Franchise Head
Spherix Global Insights
4848794284
Blaine.cloud@spherixglobalinsights.com